Stock A214450 PHARMARESEARCH CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights PharmaResearch Co., Ltd.

Equities

A214450

KR7214450009

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-06 pm EDT 		5-day change 1st Jan Change
134,900 KRW -3.37% Intraday chart for PharmaResearch Co., Ltd. +5.72% +23.20%
2023 PharmaResearch Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
2021 PHARMA RESEARCH BIO Co., Ltd. announced that it has received KRW 30 billion in funding from PharmaResearch Co., Ltd. CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PharmaResearch Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
PharmaResearch Co., Ltd. acquired Medicoson Co., Ltd.
CI
Tranche Update on Pharma Research Products Co., Ltd's Equity Buyback Plan announced on February 21, 2019.
CI
Tranche Update on Pharma Research Products Co., Ltd's Equity Buyback Plan announced on February 21, 2019.
CI
Tranche Update on Pharma Research Products Co., Ltd's Equity Buyback Plan announced on February 21, 2019.
CI
Tranche Update on Pharma Research Products Co., Ltd's Equity Buyback Plan announced on February 21, 2019.
CI
Pharma Research Products Co., Ltd's Equity Buyback announced on February 21, 2019, has expired with 129,237 shares, representing 1.37% for KRW 4,992.18 million.
CI
Pharma Research Products Co., Ltd's Equity Buyback Plan Extended till February 21, 2020.
CI
Tranche Update on Pharma Research Products Co., Ltd's Equity Buyback Plan announced on February 21, 2019.
CI
Pharma Research Products Co., Ltd announces an Equity Buyback for KRW 5,000 million worth of its shares.
CI
Pharma Research Products Co., Ltd authorizes a Buyback Plan.
CI
Pharma Research Products Co., Ltd cancelled the acquisition of Cleviel filler business segment from Aestura Corporation.
CI
Pharma Research Products Co., Ltd completed the acquisition of 42.45% stake in BIOCND Inc. from a group of shareholders.
CI
Ace Susung New Technology Fund 3, Dongyu Investment Co., Ltd and Nau Growth Capital PEF fund managed by Nau IB Capital, Investment Arm completed the acquisition of 3.2% stake in Pharma Research Products Co., Ltd from Jung, Sang-Soo.
CI
Ace Susung New Technology Fund 3, Dongyu Investment Co., Ltd and Nau Growth Capital PEF fund managed by Nau IB Capital, Investment Arm signed a stock definitive agreement to acquire 3.2% in Pharma Research Products Co., Ltd from Jung, Sang-Soo for KRW 16 billion.
CI
Promore Pharma AB Regains Rights for PXL01 Manufacturing from PharmaResearch Products Ltd
CI
Pharma Research Products Co., Ltd entered into a memorandum of understanding to acquire Cleviel filler business segment from Aestura Corporation for KRW 5.1 billion.
CI
Pharma Research Products Co., Ltd signed a memorandum of understanding to acquire 42.45% stake in BIOCND Inc. from a group of shareholders for KRW 25.9 billion.
CI
Pharma Research Products Co., Ltd cancelled the agreement to acquire 75% stake in Dr. J Skinclinic, Inc.
CI
Pharma Research Products Co Ltd acquired 2.41% in Promore Pharma AB.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A214450 Stock
  4. News PharmaResearch Co., Ltd.
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW